Allergan's Botox Will Target 1.3 Mil. Severe Primary Axillary Hyperhidrosis Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Botox for the treatment of primary axillary hyperhidrosis that is inadequately managed with topical agents. An FDA Talk Paper states patients should be evaluated for other potential causes of the problem, such as hyperthyroidism, prior to treatment.
You may also be interested in...
Patient-Reported Outcome Data Helps Dermira’s Hyperhidrosis Drug Qbrexza Win US FDA Nod
Co-primary endpoint was Axillary Sweating Daily Diary, a novel PRO instrument developed by Dermira with FDA input, assessed sweating severity and impact of sweating on a person’s daily activities; results complemented quantitative measure of sweat production in Phase III trials.
Eisai, Solstice Ink European Copromotion Deal For Botox Competitor
Firms also plan to seek several non-cosmetic indications for the biologic, for which clinical trials have shown some advantages over Allergan’s Botox, Solstice CEO tells “The Pink Sheet” DAILY.
Eisai, Solstice Ink European Copromotion Deal For Botox Competitor
Firms also plan to seek several non-cosmetic indications for the biologic, for which clinical trials have shown some advantages over Allergan’s Botox, Solstice CEO tells “The Pink Sheet” DAILY.